FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Links shared publicly online about this topic.

38
total visits

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

View full resource at news-medical.net

Tags: Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Women's Health, FDA, News, Nature

Most Recently Shared on August 29, 2011 at 6:40 am By:

News-Medical.Net

Breast Cancer News: FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection: Abbott today announce... http://t.co/FkNNCBP

9 months ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

OrganizedWisdom

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Most Recently Shared on August 29, 2011 at 6:40 am By:

Also Shared By:

Verify on Twitter to Claim Your Profile

Make an Appointment

Consulting Inquiry

Verify Information